Brief: Crossject requests pharmaceutical status to ANSM
Oct 18 (Reuters) - Crossject SA ALCJ.PA :
* Requests pharmaceutical status to ANSM (Agence Nationale de Sécurité du Médicament et des
Produits de santé)
* This step will give Crossject more autonomy to develop its own drugs based on its
self-needle injection device Zeneo
Further company coverage: ALCJ.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Crossject SA
See all newsBrief: Crossject Says Expects To File For EUA Early Next Year For Epilepsy Rescue Therapy Zepizure
Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure